![Christoph Adams](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christoph Adams
Direktor/Vorstandsmitglied bei Tiburio Therapeutics, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Mohamed Genead | M | - |
Aviceda Therapeutics, Inc.
![]() Aviceda Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aviceda Therapeutics, Inc. is a biotech company which specializes in clinical sciences, clinical research, and drug development. The firm focuses on glyco-immune therapeutics utilizing the Glyco-Code technology platform to address the innate immune system and chronic non-resolving inflammation. The company was founded by Mohamed Genead, Michael Tolentino, Derek Kunimoto, and Christopher Scott and is headquartered in Cambridge, MA. | - |
Derek Kunimoto | M | - |
Aviceda Therapeutics, Inc.
![]() Aviceda Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aviceda Therapeutics, Inc. is a biotech company which specializes in clinical sciences, clinical research, and drug development. The firm focuses on glyco-immune therapeutics utilizing the Glyco-Code technology platform to address the innate immune system and chronic non-resolving inflammation. The company was founded by Mohamed Genead, Michael Tolentino, Derek Kunimoto, and Christopher Scott and is headquartered in Cambridge, MA. | - |
Michael Tolentino | M | - |
Aviceda Therapeutics, Inc.
![]() Aviceda Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aviceda Therapeutics, Inc. is a biotech company which specializes in clinical sciences, clinical research, and drug development. The firm focuses on glyco-immune therapeutics utilizing the Glyco-Code technology platform to address the innate immune system and chronic non-resolving inflammation. The company was founded by Mohamed Genead, Michael Tolentino, Derek Kunimoto, and Christopher Scott and is headquartered in Cambridge, MA. | - |
Mette Agger | F | 59 |
Tiburio Therapeutics, Inc.
![]() Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | 6 Jahre |
Patrick Johnson | M | - |
Aviceda Therapeutics, Inc.
![]() Aviceda Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aviceda Therapeutics, Inc. is a biotech company which specializes in clinical sciences, clinical research, and drug development. The firm focuses on glyco-immune therapeutics utilizing the Glyco-Code technology platform to address the innate immune system and chronic non-resolving inflammation. The company was founded by Mohamed Genead, Michael Tolentino, Derek Kunimoto, and Christopher Scott and is headquartered in Cambridge, MA. | 1 Jahre |
Sandip Agarwala | M | 44 |
Tiburio Therapeutics, Inc.
![]() Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | 6 Jahre |
Sara Nayeem | M | 75 |
Tiburio Therapeutics, Inc.
![]() Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | - |
Nancy Thomason | F | - |
Aviceda Therapeutics, Inc.
![]() Aviceda Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aviceda Therapeutics, Inc. is a biotech company which specializes in clinical sciences, clinical research, and drug development. The firm focuses on glyco-immune therapeutics utilizing the Glyco-Code technology platform to address the innate immune system and chronic non-resolving inflammation. The company was founded by Mohamed Genead, Michael Tolentino, Derek Kunimoto, and Christopher Scott and is headquartered in Cambridge, MA. | 4 Jahre |
Paul Vukelic | M | - |
Aviceda Therapeutics, Inc.
![]() Aviceda Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aviceda Therapeutics, Inc. is a biotech company which specializes in clinical sciences, clinical research, and drug development. The firm focuses on glyco-immune therapeutics utilizing the Glyco-Code technology platform to address the innate immune system and chronic non-resolving inflammation. The company was founded by Mohamed Genead, Michael Tolentino, Derek Kunimoto, and Christopher Scott and is headquartered in Cambridge, MA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Cynthia Fisher | F | 63 |
ViaCell, Inc.
![]() ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 4 Jahre |
Kurt C. Gunter | M | 69 |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 5 Jahre |
K. Michael Forrest | M | 80 |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 3 Jahre |
Kathleen Hayes | F | - |
ViaCell, Inc.
![]() ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 4 Jahre |
Patrick Healy | M | - |
Aviceda Therapeutics, Inc.
![]() Aviceda Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aviceda Therapeutics, Inc. is a biotech company which specializes in clinical sciences, clinical research, and drug development. The firm focuses on glyco-immune therapeutics utilizing the Glyco-Code technology platform to address the innate immune system and chronic non-resolving inflammation. The company was founded by Mohamed Genead, Michael Tolentino, Derek Kunimoto, and Christopher Scott and is headquartered in Cambridge, MA. | - |
Sylvia Cheung | F | 50 |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 5 Jahre |
Christian Bloomgren | M | - |
ViaCell, Inc.
![]() ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 6 Jahre |
Anthony S. Murabito | M | - |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 2 Jahre |
Nancy J. Hull | F | - |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 5 Jahre |
Barbara Bierer | M | 70 |
ViaCell, Inc.
![]() ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 2 Jahre |
George Daley | M | - |
ViaCell, Inc.
![]() ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | - |
William J. Fallon | M | - |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 3 Jahre |
Paul Blake | M | 76 |
ViaCell, Inc.
![]() ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 2 Jahre |
Ivana Magovcevic-Liebisch | M | 55 |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 3 Jahre |
Steve G. Dance | M | 72 |
ViaCell, Inc.
![]() ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 3 Jahre |
Vaughn M. Kailian | M | 79 |
ViaCell, Inc.
![]() ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 3 Jahre |
James S. Sigler | M | 63 |
ViaCell, Inc.
![]() ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 2 Jahre |
Jonathan Leff | M | 55 |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 5 Jahre |
Jan van Heek | M | 75 |
ViaCell, Inc.
![]() ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 5 Jahre |
Daniel Geffken | M | 67 |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 6 Jahre |
James Tullis | M | 77 |
ViaCell, Inc.
![]() ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 2 Jahre |
Thomas Sciascia | M | 70 |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 1 Jahre |
Wen Bo Wang | M | - |
ViaCell, Inc.
![]() ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 32 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Christoph Adams
- Persönliches Netzwerk